发明名称 Peptidomimetic macrocycles
摘要 Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides.
申请公布号 US9175045(B2) 申请公布日期 2015.11.03
申请号 US201313957667 申请日期 2013.08.02
申请人 Aileron Therapeutics, Inc. 发明人 Nash Huw M.;Annis David Allen;Kapeller-Libermann Rosanna;Sawyer Tomi K.;Kawahata Noriyuki
分类号 A61K38/10;A61K38/12;C07K14/00;C07K7/08;C07K7/54;C07K14/47;G01N33/50 主分类号 A61K38/10
代理机构 Wilson Sonsini Goodrich & Rosati 代理人 Wilson Sonsini Goodrich & Rosati
主权项 1. A method of preparing a polypeptide with optimized cellular efficacy in human whole blood, the method comprising: (a) providing a parent polypeptide comprising a cross-linker connecting a first amino acid and a second amino acid of the parent polypeptide, and wherein the parent polypeptide penetrates cell membranes by an energy-dependent process and binds to an intracellular target; (b) producing a modified polypeptide having the same sequence as the parent polypeptide sequence except that at least one acidic side chain in the modified polypeptide is replaced with a neutral side chain; wherein the acidic side chain in the parent polypeptide is adjacent to a large hydrophobic side chain and is not essential for target binding, and wherein the modified polypeptide comprises a cross-linker connecting a first amino acid and a second amino acid of the modified polypeptide; (c) measuring an in vitro efficacy of the modified polypeptide in a whole cell assay wherein activity of the modified polypeptide is mediated by binding of the modified polypeptide to the intracellular target, in the presence and absence of human serum; (d) calculating an apparent affinity (Kd*) of the modified polypeptide to human serum proteins and an EC50 of the modified polypeptide; and (e) selecting the modified polypeptide as an optimized polypeptide if the modified polypeptide has a higher Kd* and an equal or lower EC50 than the parent polypeptide.
地址 Cambridge MA US